Overview

Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

The objectives of the study are to evaluate the pharmacokinetics (PK), safety, and efficacy of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream in subjects with cutaneous leishmaniasis (CL).

Phase:

Phase 2

Details

Lead Sponsor:

U.S. Army Medical Research and Development Command
U.S. Army Medical Research and Materiel Command

Treatments:

Gentamicins
Paromomycin